Clinical Trial Update: Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating enzastaurin added to R-CHOP in subjects with Diffuse Large B-Cell Lymphoma and the DGM1 genomic biomarker has completed and results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Enzastaurin (enzastaurin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Denovo Biopharma LLC | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2025-01-23